Research programme: epcitabine prodrugs - Idenix

Drug Profile

Research programme: epcitabine prodrugs - Idenix

Alternative Names: L-dC prodrugs - Idenix

Latest Information Update: 04 Apr 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CNRS; Idenix Pharmaceuticals; University of Alabama at Birmingham
  • Class
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 23 May 2006 No development reported - Preclinical for Hepatitis B in France (PO)
  • 23 May 2006 No development reported - Preclinical for Hepatitis B in USA (PO)
  • 09 May 2003 Novartis Pharma AG has acquired a majority equity interest in Idenix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top